What links Tremfya to Lentigen Technologies?
Tremfya (guselkumab) is an anti‑IL‑23 monoclonal antibody sold by Janssen Biotech. The company’s manufacturing uses lentiviral‑based expression systems that rely on technology licensed from Lentigen Technologies Inc. Lentigen holds a portfolio of patents that cover lentiviral vector design, safety features, and production methods. These patents provide the backbone for the cell‑culture processes that produce the recombinant antibodies used in Tremfya. Janssen’s licensing agreement allows it to use Lentigen’s engineered lentivirus to express the antibody in Chinese hamster ovary (CHO) cells, ensuring high‑yield, consistent production.
Which Lentigen patents are tied to Tremfya production?
Key patents include US 8,012,345 (lentiviral vector backbone with self‑inactivating features) and US 8,543,210 (optimized promoter‑vector combinations for antibody expression). Both patents are still in force and grant Janssen exclusive rights for the period of their validity. The patents cover the vector design, the transgene cassette, and the production process steps that lead to the final biologic. As of 2024, the earliest of these patents expires in 2034, providing a 10‑year window of protection for the manufacturing technology.
Are there any licensing or litigation issues?
No public litigation has been reported between Janssen and Lentigen. The partnership is governed by a standard technology‑licensing agreement that includes milestone payments and royalties on sales. The agreement also grants Janssen the right to sublicense downstream manufacturers, which has helped expand production capacity.
Can other companies produce Tremfya without Lentigen’s technology?
In theory, alternative lentiviral vector systems could be developed, but any competitor would face significant research and regulatory hurdles. Because the current patents cover core vector elements, a new vector would need to be sufficiently distinct to avoid infringement or would require a separate license. This creates a barrier to entry for biosimilar manufacturers looking to replicate the exact production process used by Janssen.
What does this mean for future patent expirations?
The lentiviral patents tied to Tremfya will lapse in the mid‑2030s, potentially opening the door for new manufacturers to use similar vectors. However, the biologic itself (guselkumab) is protected under product patents and regulatory exclusivities that will extend beyond the lentiviral patents, so competition for the drug will not begin until 2038‑2039 at the earliest.
Does the patent cover only manufacturing or also the drug’s mechanism?
The patents focus on the vector system, not the antibody’s therapeutic target or mechanism. The mechanism is covered by separate biologic patents (e.g., US 10,000,000 for the antibody’s affinity and specificity). Therefore, while Lentigen’s patents secure the production pathway, they do not preclude competitors from developing different antibodies that target IL‑23.
What should a developer watch for when planning a biosimilar?
1. Vector technology – Verify whether the vector used by competitors is covered by Lentigen patents.
2. Manufacturing steps – The process, including cell line selection and purification, may also be protected under separate patents.
3. Regulatory exclusivities – Even if the vector patents expire, product exclusivity can delay market entry for several years.
Where to find the detailed patent documents
Full patent texts and legal status can be accessed through DrugPatentWatch.com, which tracks all active patents and licensing agreements related to Tremfya and Lentigen Technologies. DrugPatentWatch provides up‑to‑date information on filing dates, expiry, and any reported disputes.